04 Dec Note from Dr. Aris Baras, PMWC 2018 SV Genomic Medicine Track Chair
[et_pb_section admin_label=”section” transparent_background=”off” background_color=”#ffffff” allow_player_pause=”off” inner_shadow=”off” parallax=”off” parallax_method=”off” custom_padding=”0px|||” padding_mobile=”on” make_fullwidth=”off” use_custom_width=”off” width_unit=”on” make_equal=”off” use_custom_gutter=”off” custom_padding_tablet=”-30px|||” custom_padding_last_edited=”on|desktop”][et_pb_row admin_label=”row” make_fullwidth=”off” use_custom_width=”off” width_unit=”on” use_custom_gutter=”off” custom_padding=”0px|||” padding_mobile=”on” custom_margin=”0px|||” allow_player_pause=”off” parallax=”off” parallax_method=”off” make_equal=”off” parallax_1=”off” parallax_method_1=”off” parallax_2=”off” parallax_method_2=”off” column_padding_mobile=”on” custom_padding_tablet=”0px||-50px|” custom_padding_last_edited=”on|desktop” custom_margin_tablet=”0px||-50px|” custom_margin_last_edited=”on|phone”][et_pb_column type=”4_4″][et_pb_text admin_label=”Text” background_layout=”light” text_orientation=”left” use_border_color=”off” border_color=”#ffffff” border_style=”solid” disabled=”off” disabled_on=”off|off|off” custom_margin_tablet=”-30px|||” custom_margin_last_edited=”on|phone” custom_padding_tablet=”-30px|||” custom_padding_last_edited=”on|phone” text_font=”Arial||||” text_font_size=”16″]
The Unleashed Power of Human Genetics
Over the last few years, we have witnessed a steady increase of innovations in genomic medicine. These innovative technologies and datasets are propelling us to new heights in disease understanding, diagnosis, patient stratification, and drug discovery. Human genetics applications in clinical medicine and drug development are here and now, delivering enormous innovation and impact to society.
We are entering an era of amazing growth and these technologies and applications will soon be ubiquitous in healthcare and research around the world. Millions of people have had their genes or genomes sequenced through diagnostic services, preventative screening, direct to consumer platforms, and large-scale research studies. It is expected that millions of people will be sequenced every year and that within the decade, tens to even hundreds of millions of people may have been sequenced worldwide.
The power of genetics and genomic medicine has delivered fundamental breakthroughs in rare diseases, cancer, and more broadly across common diseases. As we collectively continue to pursue, perhaps one of the greatest challenges in society, diagnosing, treating, and preventing human diseases, an expanded foundation of knowledge rooted in genetics and genomics is proving to be the critical and enabling platform that is fueling a new era of discovery and advances in medicine. There is no doubt that the impact of next-generation sequencing on genomic medicine has been tremendous – both for patients in the clinic today, receiving better health care through diagnostic and “anticipatory” medicine, and will be for patients in the future, who will have new, better medicines guided by today’s genetic discoveries.
We designed a series of three sessions for PMWC 2018 Silicon Valley that highlight leading initiatives and current advances in large scale sequencing and genomic medicine that are delivering great value to science, medicine, and patients today:
- Genetic Testing and Return of Results
- Moderator: Christa Martin (Geisinger Health)
- Panelists: Mike Snyder (Stanford), Gail Jarvik (University of Washington), Wendy Chung (Columbia), and Robert Nussbaum (Invitae)
- Large Scale Sequencing and Genetics Initiatives (January 24th AM)
- Moderator: Aris Baras (Regeneron Genetics Center)
- Panelists: David Ledbetter (Geisinger Health), Nazneen Aziz (Kaiser Permanente), Mike Gaziano (Veterans Affairs), and Peter Donnelly (Oxford)
- Genetics to Therapeutics (January 24th AM)
- Moderator: Aris Baras (Regeneron Genetics Center)
- Panelists: George Yancopoulos (Regeneron), Kari Stefansson (deCODE), and Richard Scheller (23andMe)
It’s worth mentioning that there are numerous sessions scheduled that touch upon the technological advancements of large sequence data management, processing, and analysis, knowledge extraction and reporting, and government as well as private initiatives:
-
From Target to Patient: How Machine Learning Can Deliver on the Promise of Value
- Session Chair: Diane Wuest, GNS Healthcare
- Accelerating Clinical Next-Generation Sequencing
- Session Chair: Rebecca Hemenway, Edico Genome
- Delivering Laboratory Reports That Translate into Clinical Actions for Oncologists
- Session Chair: John Shon, Illumina
- All of Us: Engaging Underrepresented Populations
- Session Chair: Dara Richardson-Heron, NIH
- AACR Project GENIE: An International Cancer Registry
- Session Chair: Alexander Baras, Johns Hopkins Hospital
- Session Chair: Alexander Baras, Johns Hopkins Hospital
- The State of Genomics Guided Clinical Decision Support
- Session Chair: Sean Scott, Qiagen
- Healthy Sequencing and Its Impact on People
- Session Chair: Justin Kao, Helix
The impact of NGS technologies on genomic medicine has been far reaching, and will surely continue in the years to come. Join us to discuss this healthcare revolution, January 22 – 24, at the Computer History Museum in the heart of the Silicon Valley, for PMWC 2018 SV.
With best regards,
Dr. Aris Baras
PMWC Genomic Medicine Track Chair
Vice President & Head
Regeneron Genetics Center
[/et_pb_text][et_pb_text admin_label=”Text-ira” background_layout=”light” text_orientation=”left” use_border_color=”off” border_color=”#ffffff” border_style=”solid” disabled=”on” disabled_on=”on|on|on” custom_margin_tablet=”-30px|||” custom_margin_last_edited=”on|phone” custom_padding_tablet=”-30px|||” custom_padding_last_edited=”on|phone” text_font=”Arial||||” text_font_size=”16″]
Together We Can Move the Needle in Cancer Immunotherapy
Immunotherapy has evolved rapidly from first promising clinical results to nothing short of revolutionizing therapy in various cancer indications. On almost a daily basis do we learn about progress in both single and combination therapies for not only disease management but lasting remissions and even cures. Despite these successes, many challenges remain. Notably in our ability to increase response rates in disease populations and difficult to treat cancer types, as well as in our understanding of the molecular mechanisms at play in order to design more targeted and patient specific treatment regimens. Furthermore, in the face of all the justified excitement we also need to remind ourselves that there are at this moment still only relatively few approved drugs in immuno-oncology.
We have very effective immune checkpoint inhibitors targeting molecules PD-L1/PD-1 and CTLA-4. This class of inhibitors and their combinations has laid the foundation for our success in the clinic, but we need to move the needle. It’s time to expand our tool kit and find additional options and innovative approaches.
One of these approaches is the CAR-T therapy (chimeric antigen receptor (CAR) T cells) which has been very promising in trials, and just approved by the FDA on August 30th. This new therapeutic approach has the potential to transform the treatment and outcomes of acute lymphoblastic leukemia – the most common cancer among young children – and lymphoma for which there are no cures today. CAR-T cells, genetically engineered immune cells, find and attack the cancer in a more precise, specific and targeted way than surgery, chemotherapy and radiation ever by repurposing the immune system to eliminate the cancer cells unique to each individual patient. And because the CAR-T cells have been trained to destroy the cancer cells, the therapy continues to work as they continue to survive and divide for months, years, and perhaps a lifetime. We’re just at the beginning of the promising and exciting future of immuno-oncology.
Given these high-impact developments in the field, PMWC 2018 Silicon Valley has dedicated seven sessions and a technology showcase to immunotherapy on day 1&2 of the program. This meeting is a great opportunity for everybody in the field to come together, learn, contribute, and “move the needle” in immunotherapy and more specifically in immuno-oncology. We have and will continue to invite a number of leading scientists and critical thought leaders who focus on various aspects of immunotherapy. Meeting sessions will include the growing area of cancer vaccines, the relevance of the tumor microenvironment, the different approaches to cell-based immunotherapies, the computationally-intensive patient selection process, and other challenges related to therapeutic discovery.
-Targeting the Tumor Microenvironment
-Cell-Based Immunotherapies
-The Promises of Combination Therapies
-Cancer Vaccines to Boost the Immune System
-Status Quo of Therapeutic Discoveries
-Challenges in Patient Selection
-Predictive Biomarkers in IO
-Total Cost Challenges of IO Care
We look forward to seeing many of you join us for the upcoming PMWC 2018 Silicon Valley conference, January 22 – 24 in Mountain View, CA to hear and discuss the latest advancements in the field of immunotherapy that are revolutionizing cancer care today.
With best regards,
Dr. Ira Mellman
PMWC Immunotherapy Track Chair
VP Cancer Immunology
Genentech
[/et_pb_text][et_pb_portfolio admin_label=”Portfolio” fullwidth=”off” posts_number=”100″ show_title=”on” show_categories=”off” show_pagination=”on” background_layout=”light” hover_overlay_color=”rgba(0,70,127,0.4)” use_border_color=”off” border_color=”#ffffff” border_style=”solid” include_categories=”152″ zoom_icon_color=”#ffffff” title_font_size=”14″ disabled=”on” disabled_on=”on|on|on”]
[/et_pb_portfolio][et_pb_text admin_label=”Text” background_layout=”light” text_orientation=”left” use_border_color=”off” border_color=”#ffffff” border_style=”solid” disabled=”on” disabled_on=”on|on|on” custom_margin_tablet=”-30px|||” custom_margin_last_edited=”on|phone” custom_padding_tablet=”-30px|||” custom_padding_last_edited=”on|phone” text_font=”Arial||||” text_font_size=”16″]
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
[/et_pb_text][et_pb_text admin_label=”Text” background_layout=”light” text_orientation=”left” use_border_color=”off” border_color=”#ffffff” border_style=”solid” disabled=”on” disabled_on=”on|on|on” text_text_color=”#000000″ text_font=”Arial||||” text_font_size=”16″]
We look forward to seeing many of you join us for the upcoming PMWC 2018 Silicon Valley conference, January 22 – 24 in Mountain View, CA to hear and discuss the latest advancements in the field of immunotherapy that are revolutionizing cancer care today.
With best regards,
Dr. Ira Mellman
PMWC Immunotherapy Track Chair
VP Cancer Immunology
Genentech
[/et_pb_text][/et_pb_column][/et_pb_row][et_pb_row admin_label=”Row” make_fullwidth=”on” use_custom_width=”off” width_unit=”on” use_custom_gutter=”off” custom_padding=”-50px||-50px|” padding_mobile=”on” custom_margin=”-50px||-50px|” allow_player_pause=”off” parallax=”off” parallax_method=”off” make_equal=”off” parallax_1=”off” parallax_method_1=”off” column_padding_mobile=”on” custom_padding_tablet=”-100px||0px|” custom_padding_last_edited=”on|desktop” custom_margin_tablet=”-100px||0px|” custom_margin_last_edited=”on|desktop” disabled=”off” disabled_on=”off|off|off”][et_pb_column type=”4_4″][et_pb_divider admin_label=”Divider – For Spacing” color=”#e2e2e2″ show_divider=”on” divider_style=”solid” divider_position=”top” hide_on_mobile=”off” custom_css_main_element=”max-width: 1200px;||margin: auto”]
[/et_pb_divider][et_pb_text admin_label=”Text – Inserted Blog” background_layout=”light” text_orientation=”left” use_border_color=”off” border_color=”#ffffff” border_style=”solid” custom_margin=”-50px|||” custom_padding=”-50px|||” custom_margin_tablet=”-125px||-125px|” custom_margin_last_edited=”on|tablet” custom_padding_tablet=”-125px||-125px|” custom_padding_last_edited=”on|tablet” disabled=”off” disabled_on=”off|off|off”]
[insert page=’blog’ display=’content’]
[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]
